Ethnicity is an independent determinant of age-specific PSA level: Findings from a multiethnic Asian setting

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Lim, Jasmine ^a   Bhoo Pathy, Nirmala ^a   Sothilingam, Selvalingam ^b   Malek, Rohan ^c   Sundram, Murali ^d   Bahadzor, Badrul Hisham ^e   Ong, Teng Aik ^a   Ng, Keng Lim ^a,f   Sivalingam, Sivaprakasam ^a   Razack, Azad Hassan Abdul ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b Hospital Tuanku Mizan   (Malaysia)

^c Selayang Hospital   (Malaysia)

^d HOSPITAL KUALA LUMPUR   (Malaysia)

^e UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANALYTICAL EQUIPMENT; ANTIGEN DETECTION; ARTICLE; ASIAN; BODY HEIGHT; BODY WEIGHT; CAUCASIAN; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIGITAL RECTAL EXAMINATION; ETHNIC DIFFERENCE; ETHNICITY; FAMILY HISTORY; HUMAN; INDIAN; JAPANESE (PEOPLE); KOREAN (PEOPLE); LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALAY (PEOPLE); MALE; POPULATION RESEARCH; PROSTATE CANCER; PROSTATE SIZE; PROTEIN BLOOD LEVEL; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; MICTURITION; MIDDLE AGED; ORGAN SIZE; PHYSIOLOGY; PROSTATE; PROSTATIC NEOPLASMS; REFERENCE VALUE;

ADULT; AGE FACTORS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-SECTIONAL STUDIES; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; URINATION;

EID: 84905833835     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104917     Document Type: Article

References (41)

1. Bunting PS, Goel V, Williams JI, Iscoe NA (1999) Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer. CMAJ 160: 70-75. (Pubitemid 29054232)
2. Sirovich BE, Schwartz LM, Woloshin S (2003) Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 289: 1414-1420. (Pubitemid 37430309)
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366: 981-990.
4. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, et al. (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104: 125-132.
5. Moyer VA (2012) Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157: 120-134.
6. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, et al. (2006) Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98: 529-534. (Pubitemid 43898816)
7. Roobol MJ (2006) The use of nomograms in the detection of prostate cancer. Prostate 66: 1266-1267.
8. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, et al. (2005) Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 173: 1930-1934. (Pubitemid 40675214)
9. Barry MJ, Fowler FJ Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, et al. (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148: 1549-1557; discussion 1564.
10. Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA (2006) Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 52: 1568-1574. (Pubitemid 44148320)
11. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, et al. (2007) Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 25: 431-436. (Pubitemid 350002992)
12. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, et al. (2001) Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58: 411-416. (Pubitemid 32816360)
13. Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ (2004) Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol 172: 90-93. (Pubitemid 41615045)
14. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, et al. (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338: b2393.
15. Xia SJ, Cui D, Jiang Q (2012) An overview of prostate diseases and their characteristics specific to Asian men. Asian J Androl 14: 458-464.
16. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, et al. (1993) Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864. (Pubitemid 23234116)
17. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, et al. (1995) Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 75: 347-353.
18. Chia SE, Lau WK, Cheng C, Chin CM, Tan J, et al. (2007) Prostate-specific antigen levels among Chinese, Malays and Indians in Singapore from a community-based study. Asian Pac J Cancer Prev 8: 375-378.
19. He D, Wang M, Chen X, Gao Z, He H, et al. (2004) Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population. Urology 63: 722-726. (Pubitemid 38479417)
20. Lee SE, Kwak C, Park MS, Lee CH, Kang W, et al. (2000) Ethnic differences in the age-related distribution of serum prostate-specific antigen values: a study in a healthy Korean male population. Urology 56: 1007-1010.
21. Smith J, Osikowicz G (1993) Abbott AxSYM random and continuous access immunoassay system for improved workflow in the clinical laboratory. Clin Chem 39: 2063-2069. (Pubitemid 23306152)
22. Vessella RL, Noteboom J, Lange PH (1992) Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. Clin Chem 38: 2044-2054.
23. Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, et al. (2006) Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 52: 59-64. (Pubitemid 43032467)
24. Lee SE, Chung JS, Han BK, Moon KH, Hwang SI, et al. (2008) Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia. Urology 71: 395-398. (Pubitemid 351374707)
25. Mao Q, Zheng X, Jia X, Wang Y, Qin J, et al. (2009) Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia. Int Urol Nephrol 41: 761-766.
26. Gupta A, Aragaki C, Gotoh M, Masumori N, Ohshima S, et al. (2005) Relationship between prostate specific antigen and indexes of prostate volume in Japanese men. J Urol 173: 503-506.
27. Kehinde EO, Mojiminiyi OA, Sheikh M, Al-Awadi KA, Daar AS, et al. (2005) Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men. BJU Int 96: 308-312. (Pubitemid 41097671)
28. Tsukamoto T, Masumori N, Nakagawa H, Arai Y, Komiya A, et al. (2009) Changes in prostate volume in Japanese patients with benign prostatic hyperplasia: association with other urological measures and risk of surgical intervention. Int J Urol 16: 622-627.
29. Khezri AA, Shirazi M, Ayatollahi SM, Lotfi M, Askarian M, et al. (2009) Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men. Iran J Immunol 6: 40-48.
30. Park DS, Oh JJ, Hong JY, Hong YK, Choi DK, et al. (2013) Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study. Asian J Androl 15: 249-253.
31. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, et al. (2007) Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298: 2275-2280. (Pubitemid 350146217)
32. Grubb RL 3rd, Black A, Izmirlian G, Hickey TP, Pinsky PF, et al. (2009) Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 18: 748-751.
33. Rosenberg MT, Staskin DR, Kaplan SA, MacDiarmid SA, Newman DK, et al. (2007) A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 61: 1535-1546. (Pubitemid 47228616)
34. Lepor H, Shapiro E, Wang B, Liang YC (1996) Comparison of the cellular composition of benign prostatic hyperplasia in Chinese and Caucasian-American men. Urology 47: 38-42. (Pubitemid 26038301)
35. Chu DI, De Nunzio C, Gerber L, Thomas JA 2nd, Calloway EE, et al. (2011) Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer Prostatic Dis 14: 346-353.
36. Freedland SJ, Platz EA, Presti JC Jr., Aronson WJ, Amling CL, et al. (2006) Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 175: 500-504; discussion 504.
37. Bushman W (2009) Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 36: 403-415, v.
38. Byun SS, Jeong H, Jo MK, Lee E (2005) Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men? Urology 66: 593-596. (Pubitemid 41242330)
39. Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, et al. (2007) Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology 69: 708-713. (Pubitemid 46574931)
40. Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, et al. (2010) Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int 105: 1554-1559.
41. Saraiya M, Kottiri BJ, Leadbetter S, Blackman D, Thompson T, et al. (2005) Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002. Cancer Epidemiol Biomarkers Prev 14: 2178-2182. (Pubitemid 41603265)